|Articles|April 16, 2010

Superior protein quality control in a user-friendly format

The Agilent 2100 Bioanalyzer plus the Agilent High Sensitivity Protein 250 Kit automatically detects and quantifies protein impurities down to 0.05% for superior Protein QC in a production-ready method!

The Agilent 2100 Bioanalyzer together with the Agilent High Sensitivity Protein 250 Kit offers unsurpassed speed, sensitivity and reproducibility for superior protein QC in a production-ready method. It detects and quantifies low concentrated impurities next to massive main components – down to 0.05% and below. This meets the ICH guideline Q3B(R2) on Impurities in New Drug Products!

Built on Agilent’s industry leading lab-on-a-chip platform, the 2100 Bioanalyzer offers:

  • Sensitivity and linear dynamic range – silver stain sensitivity down to 1 pg/μL of labeled protein on chip and 4 orders of magnitude in linear dynamic range.
  • Fast results – complete automated analysis of 10 samples in 30 minutes.
  • Reproducibility — qualitative, user-independent and digital data.
  • Ease of use — standardized assay, pre-packaged reagent kits.
  • 21 CFR Part 11 compliance — validated reagents, software, and compliance services to meet all GMP/GLP needs.

The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is perfectly suited to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines.

Learn more about the Agilent 2100 Bioanalyzer.
Request Agilent’s Protein QC Application CD!

Related to this article

Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.